End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.88 USD | +0.80% | -2.18% | +20.91% |
05-24 | Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating | MT |
05-22 | Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.91% | 3.88B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ALVO Stock
- News Alvotech
- Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab